Independent peptide education · Evidence annotated · Research use information
Peptide Library / Thymosin Alpha-1

Thymosin Alpha-1 Research Guide

Synthetic thymic peptide

Human clinical evidence; approval varies by country
ClassificationSingle Peptide
Evidence tierHuman clinical evidence; approval varies by country
Research statusEducational reference
01 · At a glance

Overview

Thymosin Alpha-1 is included in this independent research library to separate what has been demonstrated from what remains theoretical. The evidence, regulatory status and terminology vary substantially by compound, so claims should be read in the context of the cited literature.

Dosing & reconstitution guide

Thymosin Alpha-1 suggested dosing guide

A concise reference to the dosing ranges most often used in approved labeling, clinical research, or published research discussions. Evidence strength is shown so established dosing is not confused with experimental protocol.

Limited human evidence
Suggested starting range1.6 mg in many published protocols
Typical reference range1.6 mg
FrequencyTwice weekly in several approved non-US uses
TimingSpace doses across the week
Typical durationIndication dependent
RouteSubcutaneous injection

Titration and protocol notes

Approval, formulation, and protocols vary by country and indication.

Annotated dosage protocol

Each row explains what the dosage represents. Read it with the evidence badge above: labeled doses, clinical-trial doses, and commonly discussed research amounts do not carry equal clinical weight.

PhaseDoseScheduleWhat this dosage means
Lower reference1.6 mg in many published protocolsTwice weekly in several approved non-US usesThe lower end reported in research discussions; it is not a validated human starting prescription.
Commonly cited range1.6 mgSpace doses across the weekA range repeated in reference protocols. Repetition does not establish safety, efficacy, or an approved regimen.
Duration / reassessmentIndication dependentReassess before continuingApproval, formulation, and protocols vary by country and indication. Dose changes should never be inferred from vial size or convenient syringe units.

Thymosin Alpha-1 reconstitution example

This worked example uses a 10 mg vial, 2 mL of diluent, and a 1,600 mcg reference amount.

Vial strength10 mg
Diluent added2 mL
Concentration5 mg/mL
Example draw0.32 mL / 32 units
How this example is calculated: 10 mg ÷ 2 mL = 5 mg/mL. The 1,600 mcg reference amount equals 1.6 mg. That produces a 0.32 mL draw, or 32 units on a U-100 syringe.

Syringe units assume a U-100 syringe. Always verify the vial label, syringe type, formulation, and arithmetic independently.

Safety, handling, and storage
  • Suggested ranges are educational summaries, not individualized prescriptions.
  • FDA-labeled regimens apply only to the approved product, indication, and delivery system.
  • For experimental compounds, human safety, purity, and effective dosing may be unknown.
  • Follow product-specific sterility, storage, and beyond-use instructions; do not use damaged or contaminated material.
Live concentration math

Thymosin Alpha-1 calculator

Enter your laboratory values to calculate concentration, draw volume, syringe units, and portions per vial.

Runs in your browser
Concentration5 mg/mL
Draw volume0.32 mL
On the syringe32 units
Portions per vial6

Deterministic arithmetic for laboratory documentation only. This tool does not select a dose, provide a protocol, or replace qualified medical or laboratory guidance.

02 · How it is studied

Mechanism and research rationale

A 28-amino-acid peptide investigated for immune modulation, including dendritic-cell, T-cell and innate immune signaling.

Immune modulation

Infectious-disease research

Oncology adjunct research

03 · Interpretation

Key facts

  • Evidence tier: Human clinical evidence; approval varies by country.
  • Research status and regulatory status are not interchangeable.
  • This page is an educational reference and does not provide personal medical instructions.
04 · Editorial annotations

What to keep in mind

Editorial note: distinguish peer-reviewed findings from supplier or community claims.
Evidence note: study design, species, route and formulation can materially change interpretation.
05 · Sources

References and evidence indexes

  1. PubMed search: Thymosin Alpha-1
  2. ClinicalTrials.gov search
Research product

Looking for Thymosin Alpha-1?

View the corresponding Thymosin Alpha-1 research product, specifications, and available documentation from Novatherix Laboratories.

View at Novatherix →

External catalog link. For qualified laboratory and research use only.

Research notice: This guide is educational and not medical advice. It does not diagnose, treat, prescribe, or recommend personal use.